Clinical Trial Update: Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above [Phase 4]

View source ↗

Summary

This Phase 4 study update reports safety and immunogenicity data for a thiomersal-free Hepatitis E vaccine in participants aged 16 years and older.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis E

Drugs mentioned

• Hecolin (HEV-239 recombinant vaccine)

Snippet

Sponsor: Xiamen Innovax Biotech Co., Ltd | Conditions: Hepatitis E | Phase 4 | Status: COMPLETED